Background--Clinical characteristics and outcomes of takotsubo syndrome (TTS) patients with malignancy have not been fully elucidated. This study sought to explore differences in clinical characteristics and to investigate short-and long-term outcomes in TTS patients with or without malignancy.
of TTS, the exact mechanism of this entity remains uncertain. [3] [4] [5] Thus far, several case reports have described the occurrence of TTS in the setting of malignancy and chemotherapy administration. 6, 7 However, it remains unclear what role malignancy or chemotherapy play in the development in TTS with regard to physical and emotional stress. 8 It has been suggested that treatment of malignancy rather than malignancy itself is associated with the development of TTS. 9 In recent publications using data from the International Takotsubo Registry (InterTAK Registry, www.takotsubo-registry.com), we found that outcomes ofTTSinthe acutesettingcarryhighmorbidityandmortalitysimilar to that found in acute coronary syndrome (ACS). 10, 11 This poses a challenging clinical scenario where the clinical course could potentially be affected by the triple hit of malignancy, treatment, and development of TTS. Enhancing our understanding of TTS as it pertains to malignancy may aid in improving our understanding of the diagnostic workup for potential triggers of TTS, particularly those associated with a worse outcome. There is only limited data on the impact of malignancy on clinical outcomes of patients with TTS. Small scale studies have reported that malignancy might affect long-term outcomes of TTS. 12, 13 Thus, the aim of the present study was to explore differences in clinical characteristics and to investigate both short-and long-term outcomes in TTS patients with or without malignancy and to compare these outcomes to patients with ACS with or without malignancy.
Methods

Study Design
The InterTAK Registry is a multicenter collaboration comprised of 26 cardiovascular centers from 9 different countries (Austria, Finland, France, Germany, Italy, Poland, Switzerland, the United Kingdom, and United States). Data collected are observational and in part retrospective as well as prospective. The authors declare that all supporting data are available within the article. A detailed description of the rationale, design, and objectives of the InterTAK Registry has recently been published elsewhere. 14 Diagnosis of TTS was based on modified Mayo Clinic Diagnostic Criteria. 10, 15 Patients with evidence of myocarditis were excluded from the study. Additionally, the Zurich Acute Coronary Syndrome Registry, 10 a single center database of ACS patients was used to compare TTS patients from the InterTAK Registry to age-and sex-matched ACS patients. From these study populations patients were selected in whom information on malignancy was available. The study protocol was reviewed by the respective local ethics committees or investigational review boards at each collaboration site. Due to the partly retrospective nature of the study, ethics committees of most study centers waived the need for informed consent. At centers in which the ethics committees or investigational review boards required informed consent or in which patients were included prospectively, formal written consent was obtained from patients or surrogates.
Study Population and Data Collection
Of 1750 TTS patients in the InterTAK Registry, 1604 patients in whom comprehensive data on malignancy were available were included in the present analysis ( Figure 1 ). Patients were categorized into 2 groups based on the presence or absence of malignancy documentation.
For a subanalysis we included 455 TTS patients and 455 age-and sex-matched ACS patients and selected those with available information on malignancy (n=411 for TTS patients and n=441 for ACS patients, Figure 1 ). TTS patients for the matching study were included from the University Hospital Zurich, Kantonsspital Lucerne, University Hospital Basel, Mayo Clinic Rochester, and Heidelberg University Hospital, as previously described. 10 Characteristics for the comparison of TTS patients with and without malignancy included demographics, precipitating factors, cardiovascular risk factors, comorbidities, medication on admission and at discharge, laboratory values, electrocardiographic, echocardiographic, and cardiac catheterization data. Outcome data for TTS and ACS were obtained from hospital visits, medical charts, or telephone interviews. Analyses were performed within the TTS group as well as in comparison with the ACS group. In the first analysis, the TTS cohort was subdivided into patients with and without malignancy to investigate differences in patients' characteristics and to assess short-and long-term mortality. A separate analysis was performed comparing a subset of TTS patients
Clinical Perspective
What Is New?
• A substantial number of takotsubo syndrome (TTS) patients
show an association with malignancy. • The prevalence of malignancies in TTS is higher than in acute coronary syndrome. • TTS patients with malignancies have a different clinical profile including an older age at time of TTS onset and a higher prevalence of physical triggering factors.
What Are the Clinical Implications?
• The findings of the present study suggest that specific malignancy-related factors might be associated with the development of TTS. • Further research is required to investigate the interplay of malignancy and TTS, which might be helpful to elucidate the pathophysiological mechanism of TTS.
with ACS to delineate the prevalence of malignancy and longterm mortality ( Figure 1 ).
Statistical Analyses
Descriptive statistics are given as counts with percentages for categorical variables and as meanAEstandard deviation or median with interquartile range (IQR) for continuous variables. Categorical variables were analyzed by using the Pearson Chi-Square or Fisher exact test, if indicated. Student t test or Mann-Whitney U test were executed for continuous variables. Kaplan-Meier survival analysis was used to assess short-and long-term mortality and the log-rank test was applied for group comparison. A multivariable Cox-regression for long-term mortality was performed with covariates, which were statistically significant in the univariable analysis. Factors controlled for in the multivariable analysis included: age >70 years, female sex, emotional trigger, physical trigger, chest pain on admission, atrial fibrillation, heart rate >70 bpm, systolic blood pressure >130 mm Hg, maximum troponin >10 times upper limit of the normal (ULN), maximum creatine kinase >10 times ULN, C-reactive protein maximum, white blood cell count maximum, left ventricular ejection fraction (LVEF) <45%, malignancy, coronary artery disease, neurologic disorders, and psychiatric disorders. Data of covariates were 89.9% complete. Missing data were completed with multiple imputations before multivariable Cox-regression. To address clustering within countries, we repeated the Cox-regression with cluster robust standard errors adjusted for 9 countries. 
Results
Study Population
Of the total 1604 TTS patients in the InterTAK Registry, malignancy was observed in 267 (16.6%) ( Figure 1 and Figure 2 , left column). 10 The most frequent type of malignancy was breast cancer 26.2% (n=70), followed by tumors affecting the gastrointestinal system 16.1% (n=43), respiratory tract 15.4% (n=41), internal sex organs 14.6% (n=39), skin 13.1% (n=35), lymphatic system 7.1% (n=19), endocrine organs 6.7% (n=18), urinary tract 5.2% (n=14), and hematologic 3.0% (n=8) as well as the central nervous system 2.2% (n=6). In the subgroups, the overall prevalence of malignancy was 18.2% in the TTS cohort and 11.1% in the ACS cohort ( Figure 2 , middle and right column).
Patients' Characteristics
On admission, TTS patients with malignancy were older compared with those without malignancy (69.5AE11.2 years versus 65.8AE13.1 years, P<0.001), while no sex differences were observed (87.6% versus 89.8% women, P=0.29). TTS patients with malignancy on initial presentation experienced chest pain less frequently (67.8% versus 77.5%, P<0.001), but had dyspnea more often (53.5% versus 45.8%, P=0.029) ( Table 1) . Emotional stressors were less common in patients with malignancy compared with those without (18.0% versus 30.3%, P<0.001). In contrast, physical triggering factors were more often observed in TTS patients with malignancy than in those without malignancy (47.9% versus 34.2%, P<0.001). Of these, a substantial proportion of TTS patients with malignancy developed a TTS episode after a medical intervention or physical trauma (12.7% versus 5.5%, P<0.001 Outcomes TTS patients with malignancy required acute cardiac care treatment more frequently (26.7% versus 19.4%, P=0.007), predominantly due to greater need for invasive or noninvasive respiratory support (23.7% versus 15.7%, P=0.002) and had a higher in-hospital mortality (6.7% versus 3.4%, Figure 2 . Prevalence of malignancy. Prevalence of malignancy in the total study cohort of TTS patients (left column), subcohort of TTS (middle column) and ACS (right column) shows an increased prevalence of malignancy in TTS when compared with ACS. 10 If a patient had a history of >1 malignancy then the patient was categorized into all respective groups of malignancies. ACS indicates acute coronary syndrome; TTS, takotsubo syndrome. P=0.010). While 30-day mortality did not differ between TTS patients with and without malignancy (P=0.17; Figure 3 , inset), long-term survival analyses showed a higher mortality in TTS patients with malignancy (P<0.001; Figure 3 Figure 4 ) and TTS patients without malignancy also showed a comparable outcome with ACS patients without malignancy (P=0.54, Figure 4 ). Results of multivariable analysis in the entire cohort of 1604 TTS patients demonstrated that age >70 years, atrial fibrillation, peak troponin >10x ULN, peak creatinine kinase >10x ULN, LVEF <45%, malignancy, neurologic conditions, and psychiatric disorders were independent predictors of long-term mortality ( Figure 5 ). Results remained similar when assessing clustering among countries ( Figure S1 ).
Discussion
Leveraging on the largest database of TTS patients published thus far, we have provided a more detailed analysis of prevalence and outcome of patients with malignancy and TTS.
Here we show that TTS and ACS patients with malignancies have comparable long-term outcomes. Furthermore, we found that in TTS patients with malignancy, the inciting event is an emotional trigger less frequently than in those without malignancy. Even though the psychological burden of a malignancy diagnosis could potentially increase sympathetic output, this was not the case in our analysis as emotional stressors were less common in patients with malignancy compared with those without. It is noteworthy that the prevalence of psychiatric disorders including anxiety and depression was not significantly different in TTS patients with malignancy compared to without malignancy. With regard to inflammatory markers, while the total number of white blood cell counts were not different between the groups, C-reactive protein levels were significantly higher in the TTS patients with malignancy in those without malignancy, likely a marker of the greater comorbidity burden. While multiple theories have been postulated to explain the pathophysiology of TTS, the exact mechanisms of this acute transient decrease in left ventricular function remain uncertain. 1, 4, 5 The relationship between malignancy and TTS is particularly interesting from an epidemiologic, mechanistic, and outcome standpoint as malignancy and chemotherapy have been associated with TTS. 9, 12, [16] [17] [18] [19] Endothelial dysfunction in epicardial and microvascular coronary arteries occurs frequently in patients with cancer, 20 especially during and after systemic chemotherapy or radiotherapy of the heart region, which might be a predisposing factor for developing TTS. Therefore, assessment of endothelial function, such as acetylcholine spasm provocation testing, would probably be useful in further defining mechanisms in this patient population. Interestingly, the prevalence of malignancy in our TTS cohort exceeded the reported rates of the general population in Europe 21 . Another investigation reported that underlying cardiac comorbidities were independent predictors of long-term mortality in patients with TTS. 22 Also in this cohort, malignancy was more common in those patients who did not survive long-term. This is of particular interest since data from our registry further reveal a strong association between TTS and malignancy. Moreover, in a recent publication using data from the InterTAK Registry, we demonstrated that outcomes of TTS in the acute setting carry a high morbidity and mortality similar to ACS and that the prevalence of malignancy in TTS exceeds that of ACS. 10, 23 This poses a challenging clinical scenario in the management of patients with malignancy. Not only does TTS carry a high rate of mortality similar to that of ACS, 10 its concomitant diagnoses in malignancy patients may pose worse outcomes. As there are no standardized guidelines regarding screening or risk stratification for TTS in patients with malignancy, understanding potential underlying causes and the clinical importance of the association of TTS and malignancy may help improve clinical outcomes. As such, it is reasonable to consider malignancy as a potential triggering factor of TTS. Additionally, in certain patients TTS may be considered a paraneoplastic syndrome, a harbinger for the presence of underlying malignancy. Alternatively, metabolic and/or neurohumoral changes associated with malignancy may increase the likelihood of a TTS episode. Even if the relationship between developing TTS and malignancy cannot be deemed causative, screening for malignancy in those with acute episodes of TTS can perhaps prompt further therapy and improve overall outcomes. 24 The numerous effects of malignancy and therapies on the heart are evidenced by the rapid evolution of the field of cardiooncology. As such the malignancy patient subset of TTS provides a unique milieu to investigate possible etiologic factors of the interaction between the 2 disease entities and their treatment. Furthermore, studies focusing on the timerelationship of cancer therapies, such as chemotherapy, immunotherapy, and radiation treatment, and onset of TTS is essential to elucidate the relationship between TTS and cancer. presence or absence of malignancy. Kaplan-Meier survival analysis showed that patients with malignancy had significantly worse outcome than those without malignancy both in patients with TTS and ACS. In addition, TTS patients with malignancy had a comparable long-term outcome with ACS patients with malignancy (P=0.13) and TTS patients without malignancy also showed a comparable outcome with ACS patients without malignancy (P=0.54). ACS indicates acute coronary syndrome; TTS, takotsubo syndrome.
Limitations
To study the relationship between TTS and cancer is challenging as questions remain as to whether the worse prognosis is related to the presence and specific type, stage, and treatment for malignancy, the presence of TTS, or a combination of these factors. In addition, the different type and stage of cancer might affect the outcome, however, the Results of the multivariable Cox-regression in the total cohort of TTS patients showed that age >70 years, atrial fibrillation, maximum troponin >10x ULN, maximum creatinine kinase >10x ULN, left ventricular ejection fraction <45%, malignancy, neurologic disorders, and psychiatric disorders are independent predictors of longterm mortality. Error bars represent 95% CI. Black rhombi indicate statistical significance; grey rhombi not statistically significant. CI indicates confidence interval; HR, hazard ratio; ULN, upper limit of the normal range. number of patients with certain type or stage of cancer is too small for a meaningful comparison analysis in our cohort.
Conclusions
The findings of the present study have unraveled a high prevalence of malignancy in TTS patients. Additionally, our analyses illustrate the clinical course and unique characteristics in TTS patients with or without malignancy as compared to a cohort of ACS patients. Our findings suggest that specific malignancy-associated factors impact the development and outcome of TTS. Therefore, to fully understand the pathophysiology of TTS and the role of malignancy in triggering or affecting outcomes, this subset of patients deserves further investigation. These factors may include analysis of specific malignancy types and metabolic and neurohumoral changes associated with it and/or the effects of distinct therapeutic molecules administered in such patients. Therefore, developing specific quantifiable metrics relevant to this unique patient population to improve outcomes is warranted. 
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